Clinical Investigation - Unequal Arterial Stiffness With Overall and Cardiovascular Mortality in Patients Receiving Hemodialysis. (February 2016)

• Record Type: Journal Article
• Authors: Wei, Shu‐Yi; Huang, Jiun‐Chi; Chen, Szu‐Chia; Chang, Jer‐Ming; Chen, Hung‐Chun
• Is Part Of: American journal of the medical sciences. Volume 351:Number 2(2016)
• Publication Date: 2016-02
• Subjects: Brachial‐ankle pulse wave velocity difference -- Hemodialysis -- Overall and cardiovascular mortality; Medicine -- Periodicals; Internal medicine -- Periodicals; 610.5
• DOI: 10.1016/j.amjms.2015.11.017
• Languages: English
• ISSNs: 0002-9629

Abstract

ABSTRACT : Background: : Pulse wave velocity is a marker of arterial stiffness. Unequal arterial stiffness has been associated with increased risk of cardiovascular events. This study calculated bilateral brachial‐ankle pulse wave velocity (baPWV) differences and investigated the associations of unequal bilateral baPWV with overall and cardiovascular mortality in patients receiving hemodialysis (HD). Materials and Methods: : A total of 205 patients receiving HD were enrolled in this study. The mean follow‐up period was 4.4 ± 1.5 years. The baPWV was measured using an ankle‐brachial index‐form device, and bilateral baPWV difference was calculated and defined as ΔbaPWV. Results: : The median value of ΔbaPWV was 88 cm/second. ankle‐brachial index < 0.95 and high baPWV were independently associated with a ΔbaPWV ≥ 88 cm/s. Furthermore, patients with a ΔbaPWV ≥ 88 cm/s demonstrated poorer overall (log‐rank P = 0.035) and cardiovascular (log‐rank P = 0.036) survival than did those with a ΔbaPWV < 88 cm/s. After multivariate analysis, this difference was independently associated with overall (hazard ratio = 1.006; 95% CI: 1.001‐1.011; P = 0.024) and cardiovascular (hazard ratio = 1.006; 95% CI: 1.000‐1.013; P = 0.049) mortality. Conclusions: : ΔbaPWV was associated with an increased risk of cardiovascular and overall mortality in patients receiving HD. Earlier evaluation of ΔbaPWV may facilitate the identification of patients receiving HD who have an increased risk of cardiovascular and overall mortality.